C

Celularity

Biotech & Life Sciences · Florham Park, United States · Founded 2016 · Public via SPAC 2019

Celularity Inc. operates as a clinical and commercial-stage biotechnology firm, positioning itself at the nexus of cellular and regenerative medicine. Founded in 2017 as a spin-out from Celgene, the company is the culmination of pioneering work by its founder, Dr. Robert Hariri, a surgeon and biomedical scientist who first identified the therapeutic potential of the human placenta. Dr. Hariri's journey began with the founding of Anthrogenesis in 1998, which was later acquired by Celgene in 2002, laying the groundwork for what would become Celularity. His fascination with the placenta as a source for stem cells led to a career dedicated to developing therapies from this often-discarded biological material. Celularity went public in 2021 via a merger with GX Acquisition Corp. and trades on Nasdaq under the ticker 'CELU'. The company's business model is twofold, combining a clinical-stage pipeline of cellular therapies with a commercial-stage business centered on biomaterial products and biobanking services. This dual approach allows Celularity to generate revenue to support its extensive research and development activities. Revenue streams include the sale and licensing of advanced biomaterial products like Biovance and Interfyl for surgical and wound care, and fees from its LifebankUSA brand, which provides private stem cell banking services. Additionally, the company generates revenue by offering its manufacturing capabilities to other cell therapy companies, as seen in its collaboration with BlueSphere Bio. Celularity's core focus is harnessing the postpartum placenta to create "off-the-shelf" allogeneic cellular therapies that do not require patient-donor matching. This source material provides a scalable and readily available foundation for its therapeutic candidates. The company's investigational pipeline includes unmodified natural killer (NK) cells, genetically modified NK cells, and CAR T-cells designed to target cancers and other diseases. One of its key candidates, CYNK-001, an unmodified NK cell therapy, has been investigated for treating acute myeloid leukemia (AML) and malignant gliomas. Beyond oncology, the company is exploring treatments for autoimmune disorders, and degenerative diseases. The company’s Celularity IMPACT platform serves as the foundation for developing these therapies. Headquartered in Florham Park, New Jersey, Celularity operates with a substantial intellectual property portfolio, including over 800 issued patents related to placental-derived cells. The company has engaged in multiple clinical trials to evaluate the safety and efficacy of its product candidates, such as a Phase 2 study of PDA-002 for diabetic foot ulcers. Despite its clinical progress, the company has faced financial challenges, disclosing in SEC filings a need for additional financing and substantial doubt about its ability to continue as a going concern. Keywords: Celularity, allogeneic cell therapy, placenta-derived cells, regenerative medicine, Robert Hariri, clinical-stage biotechnology, off-the-shelf therapies, NK cell therapy, CAR T-cell, CYNK-001, cancer immunotherapy, degenerative diseases, biomaterial products, Biovance, LifebankUSA, cellular medicine, stem cell banking, Anthrogenesis, Celgene spin-out, immuno-oncology, tissue engineering, functional regeneration, PDA-002, autoimmune disorders, Florham Park, umbilical cord blood, advanced biomaterials